Skip to main content

Advances in Small Trials dEsign for Regulatory Innovation and eXcellence

Objectif

"ASTERIX will contribute towards the expected impact listed in the work program by delivering validated innovative statistical design methodologies for cost efficient clinical trials deriving reliable results from trials in small population groups, especially focusing on rare diseases. It directly addresses the rights of the estimated 30 million European patients suffering from rare diseases to the same quality or treatment as other patients. By choosing an integrated approach leveraging statistical methods, smartly combining observational and clinical data as well as improved sequential and adaptive approaches ASTERIX will improve statistical power of clinical trial design in small populations. ASTERIX will systematically include patients and the patient perspective into its research, but moreover develop the approach to involve patients in clinical trial design in a methodological sound manner. Pre-clinical data, historical data on disease characteristics, and benefit and risk as perceived by patients will systematically inform and weigh relevant endpoint measures. Thus the clinical value of trial results will be enhanced considerably. Key methodological innovations include: new standards of evidence that take into account the rare prevalence of disease, leveraging prior information and the availability of multiple endpoints, enabling adaptive designs and sequential meta-analysis using multiple endpoints and providing a blue print to pro-actively share information on trials in the planning stage. The latter will ensure that each new trial in an orphan disease provides the optimum additional knowledge for patient treatment. Relevance and clinical value of the newly designed methodological approaches are validated twofold. Firstly, by cross testing with available clinical trial data of a broad range of highly relevant rare diseases and secondly, by assessing the methods against current and improved regulatory approval strategies."

Appel à propositions

FP7-HEALTH-2013-INNOVATION-1
Voir d’autres projets de cet appel

Coordinateur

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Adresse
Heidelberglaan 100
3584 CX Utrecht
Pays-Bas

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Caroline Van Baal (Dr.)
Contribution de l’UE
€ 750 058

Participants (6)

MEDIZINISCHE HOCHSCHULE HANNOVER
Allemagne
Contribution de l’UE
€ 525 200
Adresse
Carl-neuberg-strasse 1
30625 Hannover

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Frank Dittrich (Mr.)
MEDIZINISCHE UNIVERSITAET WIEN
Autriche
Contribution de l’UE
€ 515 401
Adresse
Spitalgasse 23
1090 Wien

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Wolfgang Dorda (Prof.)
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Pays-Bas
Contribution de l’UE
€ 466 640
Adresse
Meibergdreef 15
1105AZ Amsterdam

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Sylvia Georgiev (Ms.)
UNIVERSIDAD AUTONOMA DE BARCELONA
Espagne
Contribution de l’UE
€ 512 442
Adresse
Calle Campus Universitario Sn Cerdanyola V
08290 Cerdanyola Del Valles

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Francisca Rabadán Sotos (Ms.)
STATISTICIANS IN THE PHARMACEUTICALINDUSTRY LIMITED LBG
United Kingdom
Contribution de l’UE
€ 68 150
Adresse
Durford Mill
GU31 5AZ Petersfield

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Alun Bedding (Mr.)
VERENIGING SAMENWERKENDE OUDER- EN PATIENTENORGANISATIES
Pays-Bas
Contribution de l’UE
€ 161 990
Adresse
Vredehofstraat 31
3761HA Soest

Voir sur la carte

Type d’activité
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contact administratif
Cor Oosterwijk (Mr.)